Spectral Medical (EDT) AI Stock Analysis

• Market Cap: $210.99M
• Dividend Yield: N/A
• Average Volume (3M): 63.88K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.15
• Revenue Growth: 43.05%
• EPS Growth: 2.14%
• Country: CA
• Employees: 29
• Sector: Healthcare
• Sector Strength: 71
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.06
• Shares Outstanding: 285,117,220
• 10 Day Avg. Volume: 57,285
• 30 Day Avg. Volume: 63,876
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 104.38
• Price to Cash Flow (P/CF): -20.70
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Spectral Medical's stock score reflects significant financial challenges, with persistent losses and negative cash flows raising concerns about financial stability. However, recent corporate developments, including progress in a pivotal clinical trial, provide potential upside. Technical analysis suggests positive momentum, though valuation metrics are weak due to a lack of profitability. Overall, while there are promising clinical advancements, the financial and valuation concerns weigh heavily on the stock's outlook.

Spectral Medical Business Overview & Revenue Model

Company Description

Spectral Medical Inc. (EDT) is a medical diagnostics and therapeutics company that specializes in the development and commercialization of innovative products for the treatment of severe sepsis and septic shock. The company is known for its proprietary endotoxin activity assay (EAA) and the Toraymyxin therapy, which are designed to help healthcare professionals manage and treat endotoxin-related illnesses.

How the Company Makes Money

Spectral Medical generates revenue primarily through the sales of its medical diagnostic products and therapeutic solutions, such as the endotoxin activity assay (EAA) and Toraymyxin therapy. The company collaborates with hospitals and healthcare facilities to implement its diagnostic tests and therapeutic treatments, thereby driving sales. Additionally, Spectral Medical may engage in partnerships or licensing agreements with other medical and pharmaceutical companies to expand the reach and application of its technologies, contributing to its earnings. The company's revenue streams are largely dependent on the adoption of its products within the healthcare sector and its ability to maintain and grow its market presence.

Spectral Medical Financial Statement Overview

Summary

Spectral Medical faces significant financial challenges, characterized by consistent losses and negative cash flows. Increasing total debt and negative equity raise concerns about financial stability and solvency. The company's ability to improve its financial health is uncertain without a strategic turnaround.

Income Statement

Revenue has shown volatility with a decline from 2019 to 2020, followed by fluctuations in subsequent years. The company has consistently reported negative net income, leading to negative net profit margins. EBITDA margin is also negative, indicating operational challenges. Despite a slight increase in gross profit in 2024, profitability remains a concern.

Balance Sheet

The company shows a negative stockholders' equity position since 2020, indicating potential solvency issues. The debt-to-equity ratio is not calculable due to negative equity, but total debt has increased significantly, raising leverage concerns. Total liabilities have grown, impacting financial stability.

Cash Flow

Operating cash flow remains negative, with no positive free cash flow reported in the past years. While financing cash flow has been positive, it primarily supports operating activities, not growth. The negative free cash flow to net income ratio indicates cash flow challenges.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
2.29M	1.60M	1.67M	2.05M	2.10M
	Gross Profit
1.02M	662.00K	983.00K	1.22M	1.47M
	EBIT
0.00	-11.42M	-9.44M	-8.60M	-9.09M
	EBITDA
-11.97M	-13.96M	-7.18M	-6.64M	-8.76M
	Net Income Common Stockholders
-15.40M	-15.66M	-11.30M	-8.72M	-8.98M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
2.99M	2.95M	8.41M	8.89M	5.81M
	Total Assets
5.32M	5.21M	12.00M	11.55M	8.16M
	Total Debt
14.93M	8.56M	6.64M	582.00K	667.00K
	Net Debt
11.94M	5.61M	-1.77M	-8.31M	-5.14M
	Total Liabilities
32.87M	21.76M	14.52M	7.47M	8.83M
	Stockholders Equity
-27.55M	-16.55M	-2.52M	4.08M	-669.00K
Cash Flow		Free Cash Flow
-8.85M	-10.91M	-9.96M	-9.18M	-639.00K
	Operating Cash Flow
-8.82M	-10.72M	-9.93M	-8.70M	-324.00K
	Investing Cash Flow
-27.00K	-185.00K	-33.00K	-325.00K	-297.00K
	Financing Cash Flow
8.88M	5.44M	9.48M	12.16M	5.18M

Spectral Medical Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.78
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:EDT, the sentiment is Positive. The current price of 0.78 is above the 20-day moving average (MA) of 0.72, above the 50-day MA of 0.69, and above the 200-day MA of 0.60, indicating a bullish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 57.84 is Neutral, neither overbought nor oversold. The STOCH value of 55.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:EDT.

Spectral Medical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HLS	54 Neutral	C$137.03M	―	-23.20%	―	-8.80%	26.77%
EDT	50 Neutral	$210.99M	―	80.28%	―	43.05%	2.14%
Sector *	50 Neutral	$5.51B	2.95	-43.70%	2.78%	16.94%	3.59%

Spectral Medical Corporate Events

Spectral Medical Nears Completion of Key Clinical Trial for Sepsis Treatment

Spectral Medical announced its financial results for the fourth quarter and fiscal year 2024, highlighting significant clinical and operational progress. The company is nearing full enrollment in its Phase III Tigris trial, which evaluates PMX for endotoxic septic shock, and is working towards FDA submission. Despite challenges such as Hurricane Helene impacting the medical supply chain, enrollment has been robust, with 154 patients enrolled to date. Spectral is also collaborating with Vantive on commercialization plans, anticipating a positive trial outcome and preparing for PMX’s market launch. The completion of the Tigris study and the PrisMax sub-study are key milestones that could enhance Spectral’s industry positioning and stakeholder value.

Spectral Medical Nears Completion of Phase 3 Tigris Trial for Sepsis Treatment

Spectral Medical Inc. has announced an update on its Tigris trial, a Phase 3 study evaluating the use of Polymyxin B Hemoperfusion (PMX) for treating endotoxemia and septic shock. With 152 patients enrolled, the trial is nearing its target of 150 evaluable patients, expected to be reached by the end of March 2025. The completion of this trial is crucial for PMX’s regulatory review, particularly concerning safety and secondary analyses, which could significantly impact Spectral’s market positioning and stakeholder interests.

Spectral Medical Nears Full Enrollment in Tigris Trial for Sepsis Treatment

Spectral Medical provided an update on its Tigris trial, a Phase 3 study evaluating the use of PMX in treating endotoxemia and septic shock. The company has enrolled 146 patients so far, aiming to reach 150 by the end of Q1 2025. The trial is significant for Spectral’s efforts to secure FDA approval in the U.S., enhancing its market position and potentially benefiting stakeholders involved in addressing septic shock, which affects approximately 330,000 patients in North America annually.